Skip to main content
Jeremy Schmahmann, MD, Neurology, Boston, MA, Massachusetts General Hospital

JeremySchmahmannMD

Neurology Boston, MA

Movement Disorder, Neurodegenerative, Dementia & Geriatrics

Professor of Neurology at Harvard Medical School, Director of the MGH Ataxia Unit

Dr. Schmahmann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Schmahmann's full profile

Already have an account?

Education & Training

  • Boston Medical Center
    Boston Medical CenterPost-Doctoral Fellowship, Neuroanatomy and Neurobiology, 1985 - 1988
  • Boston City Hospital
    Boston City Hospital1982 - 1985
  • University of Cape Town Faculty of Medicine
    University of Cape Town Faculty of MedicineClass of 1980

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1985 - Present
  • MA State Medical License
    MA State Medical License 1985 - 2025
  • NH State Medical License
    NH State Medical License 2023 - 2025
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • Best Doctors in America Best Doctors, 1996-2015
  • Distinguished Neurology Teacher Award ANA, 2008
  • Norman Geschwind Prize AAN and Behavioral Neurology Society, 2000

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Congrats to the 44 Mass General Investigators Named to the Highly Cited Researchers List for 2022
    Congrats to the 44 Mass General Investigators Named to the Highly Cited Researchers List for 2022December 8th, 2022
  • Congrats to the 44 Mass General Investigators Named to Clarivate Analytics’ Highly Cited Researchers List for 2022
    Congrats to the 44 Mass General Investigators Named to Clarivate Analytics’ Highly Cited Researchers List for 2022November 22nd, 2022
  • Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
    Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)May 23rd, 2022
  • Join now to see all

Professional Memberships

Hospital Affiliations